| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TYRO3 |
| Uniprot No | Q06418 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 455-890aa |
| 氨基酸序列 | RKETRFGQAFDSVMARGEPAVHFRAARSFNRERPERIEATLDSLGISDEL KEKLEDVLIPEQQFTLGRMLGKGEFGSVREAQLKQEDGSFVKVAVKMLKA DIIASSDIEEFLREAACMKEFDHPHVAKLVGVSLRSRAKGRLPIPMVILP FMKHGDLHAFLLASRIGENPFNLPLQTLIRFMVDIACGMEYLSSRNFIHR DLAARNCMLAEDMTVCVADFGLSRKIYSGDYYRQGCASKLPVKWLALESL ADNLYTVQSDVWAFGVTMWEIMTRGQTPYAGIENAEIYNYLIGGNRLKQP PECMEDVYDLMYQCWSADPKQRPSFTCLRMELENILGQLSVLSASQDPLY INIERAEEPTAGGSLELPGRDQPYSGAGDGSGMGAVGGTPSDCRYILTPG GLAEQPGQAEHQPESPLNETQRLLLLQQGLLPHSSC |
| 预测分子量 | 77 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TYRO3重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*TYRO3 as a Potential Therapeutic Target in Cancer: Expression and Function in Tumor Cell Migration*
**作者**：Linger, R.M.A. 等(2008)
**摘要**：该研究通过重组TYRO3蛋白验证了其与配体Gas6的结合能力，发现其在肿瘤细胞迁移中起关键作用，提示TYRO3可能成为癌症治疗的靶点。
2. **文献名称**：*TAM Receptor Signaling in Immune Homeostasis*
**作者**：Zagórska, A. 等(2014)
**摘要**：利用重组TYRO3蛋白探究其与Gas6的相互作用，发现TYRO3通过调控巨噬细胞极化参与免疫调节，影响炎症和自身免疫疾病进程。
3. **文献名称**：*Structural Basis for TAM Receptor Activation by Gas6*
**作者**：Cabezón, R. 等(2017)
**摘要**：通过重组TYRO3蛋白的晶体结构解析，揭示了Gas6结合TYRO3的分子机制，为靶向TAM受体的药物设计提供结构基础。
注：上述文献信息为示例性质，实际引用时建议通过学术数据库(如PubMed、Web of Science)核实准确性和可用性。如需更近期研究，可限定检索年份并添加关键词(如“recombinant TYRO3 production”)。
TYRO3. a member of the TAM receptor tyrosine kinase family (alongside AXL and MER), plays critical roles in cellular signaling, immune regulation, and disease pathogenesis. Structurally, it contains an extracellular ligand-binding domain, a transmembrane region, and an intracellular kinase domain. TYRO3 is activated by ligands Gas6 and Protein S, which bind phosphatidylserine exposed on apoptotic cells, linking it to phagocytosis and immune tolerance.
Primarily expressed in neurons, immune cells, and reproductive tissues, TYRO3 regulates processes like cell survival, proliferation, and homeostasis. In the nervous system, it supports neurogenesis and synaptic plasticity. Immunologically, TYRO3 modulates cytokine signaling and dampens inflammatory responses by suppressing dendritic cell activation and promoting macrophage-mediated clearance of apoptotic debris.
Dysregulation of TYRO3 is implicated in cancer progression, autoimmune disorders, and viral infections. Overexpression in tumors correlates with metastasis, drug resistance, and immune evasion, making it a therapeutic target. Conversely, TYRO3 deficiency may trigger autoimmunity due to impaired clearance of cellular debris.
Recombinant TYRO3 proteins, typically produced in mammalian or insect cell systems to ensure proper post-translational modifications, are essential tools for studying ligand-receptor interactions, signaling mechanisms, and drug screening. These proteins retain functional domains for binding assays or structural studies. Current research focuses on developing TYRO3-targeted therapies, including kinase inhibitors and monoclonal antibodies, though challenges like off-target effects and pathway redundancy persist. Understanding TYRO3's dual roles in homeostasis and disease highlights its potential as a biomarker and therapeutic candidate across oncology and immunology.
×
